Bis-hexamethylene triamine appears as a colorless crystalline or flaked solid. Corrosive. Irritating to skin and eyes. May be toxic by ingestion. Used to make plastics.
稳定性/保质期：
常温常压下稳定。
禁配物：强氧化剂
计算性质
辛醇/水分配系数(LogP)：
0.8
重原子数：
15
可旋转键数：
12
环数：
0.0
sp3杂化的碳原子比例：
1.0
拓扑面积：
64.1
氢给体数：
3
氢受体数：
3
ADMET
毒理性
副作用
职业性肝毒素 - 第二性肝毒素：在职业环境中的毒性效应潜力是基于人类摄入或动物实验的中毒案例。
Occupational hepatotoxin - Secondary hepatotoxins: the potential for toxic effect in the occupational setting is based on cases of poisoning by human ingestion or animal experimentation.
来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases
毒理性
TSCA 测试提交
己二胺 (CAS # 143-23-7) 在对5组斯普拉格-道利白化大鼠(每组2或3只/性别)进行急性经口毒性评估时，通过口服灌胃单一未稀释剂量316、398、501和631 mg/kg。在三个最高剂量组中，死亡发生在1到2小时内，根据E. J. de Beer的方法计算，LD50为450 (415-485) mg/kg。临床毒性特征表现为食欲减退、活动减少、迅速失去活力、虚脱和死亡。在对研究致死性的尸检中，发现了出血性肺和肝以及严重的胃肠炎。在灌胃后7天的观察期内存活下来的大鼠没有出现可归因于治疗的明显病理变化。
bis-Hexamethylenetriamine (CAS # 143-23-7) was evaluated for acute oral toxicity in groups of 5 Sprague-Dawley albino rats (2 or 3/sex/group) administered single undiluted doses of 316, 398, 501, and 631 mg/kg by oral gavage. Mortality occurred within 1 to 2 hours in the three highest dose groups, and an LD50 was 450 (415-485) mg/kg, as calculated by a method of E. J. de Beer. Clinical toxicity was characterized by reduced appetite, hypoactivity, rapid loss of vigor, collapse, and death. Upon necropsy of the study lethalities, hemorrhagic lungs and liver, and profound gastrointestinal inflammation were identified. The survivors of 7-day post-gavage observation exhibited no gross pathology attributable to treatment.
bis-Hexamethylenetriamine (CAS # 143-23-7) was evaluated for acute dermal toxicity in alternate solitary male or female New Zealand white rabbits administered single occluded applications of 31.6, 50.1, 79.4, 126.0, 200.0, 316.0, 1000.0, and 2000.0 mg/kg neat upon clipped, intact skin for 24 hours. An LD50 range was identified between 126.00 and 200.0 mg/kg, with each rabbit of a 200.0 mg/kg dose or higher succumbing from several hours to one day post-treatment. Reduced appetite, hypoactivity, increasing loss of vigor, collapse, and death characterized the clinical evidence of systemic toxicity. Upon necropsy, macroscopic evidence of systemic toxicity associated with treatment was identified among the decedent rabbits, including hemorrhagic lungs and liver. The study survivors of 14-day post-treatment observation exhibited no gross lesions.
bis-Hexamethylenetriamine (CAS # 143-23-7) was evaluated for eye irritation in 2 groups of 3 (2 male, 1 female) albino rabbits (strain unspecified) administered single 0.1 mL undiluted instillations into right eye conjunctival sacs for 1 minute and 24 hours, respectively. Treatment was terminated upon saline wash of the treated eyes. Determinations of irritation at 10 minutes, 1 hour, and at 3, 5, 7 and 14 days post-treatment were made based on a method of Draize, Woodard, and Calvery, the left (untreated) eyes serving as control. All instillations induced severe discomfort, with pawing, squealing, and thrashing about in the cages. One hour after rinse of the 1-minute instillation, the initial severe erythema, slight edema and copious discharge had worsened to severe erythema, moderate edema, copious discharge, and corneal dullness. Rabbits of the 24-hour treatments exhibited a similar response to unrinsed instillations by 10 minutes. Increasing corneal cloudiness in the animals of 1-minute instillations eventuated in corneal opacity and destroyed vision at 120 hours, a fate that was realized in rabbits of 24-hour treatments at 1 hour post-instillation.
Bis(hexamethylene)triamine (CAS # 143-23-7) was evaluated for primary dermal irritation in 3 male and female New Zealand white rabbits administered 0.5 mL undiluted applications upon clipped, intact skin under semi-occluded patch for 4 hours. Dermal discoloration from the sample continued to prevent appreciation of erythema at 1-hour post-dosing, although edema was noted and worsened to eschar by the 4-hour evaluation. Slight loosening of scab edges at the reaction site was reported 14 days after treatment. Based on a method of Draize, Woodard, and Calvery, the study authors classified the compound as corrosive.
六亚甲基二胺（HMDA）是合成6,6尼龙的重要试剂，通常通过使用有毒氢氰酸的试剂对己二腈进行氢化来生产。本文中，我们开发了一种环境友好的途径，可在氢气存在下通过1,6-己二醇（HDO）的催化还原胺化来生产HMDA。在没有任何添加剂的超临界氨中，针对本反应筛选了几种非均相金属催化剂如负载型Ni，Co，Ru，Pt，Pd催化剂的活性。在所研究的催化剂中，Ru / Al 2 O 3对所需的HMDA产物具有高催化活性和最高选择性。高性能Ru / Al 2 O 3基于Ru的分散性和酸碱度等表面性质进行了讨论。另外，还考察了反应温度，时间，H 2和NH 3压力等反应参数，并对反应过程进行了详细讨论。
[EN] INTEGRATED PROCESS FOR NITRILE MANUFACTURE WITH ENHANCED LIQUID-LIQUID EXTRACTION [FR] PROCÉDÉ INTÉGRÉ DE PRODUCTION DE NITRILE PAR UNE EXTRACTION LIQUIDE-LIQUIDE AMÉLIORÉE
USE OF NITROGEN COMPOUNDS QUATERNISED WITH ALKYLENE OXIDE AND HYDROCARBYL-SUBSTITUTED POLYCARBOXYLIC ACID AS ADDITIVES IN FUELS AND LUBRICANTS
申请人：BASF SE
公开号：US20160130514A1
公开（公告）日：2016-05-12
The invention relates to the use of quaternized nitrogen compounds as a fuel and lubricant additive or kerosene additive, such as in particular as a detergent additive, for decreasing or preventing deposits in the injection systems of direct-injection diesel engines, in particular in common rail injection systems, for decreasing the fuel consumption of direct-injection diesel engines, in particular of diesel engines having common rail injection systems, and for minimizing the power loss in direct-injection diesel engines, in particular in diesel engines having common rail injection systems; the invention further relates to the use as an additive for petrol, in particular for operation of DISI engines.
[EN] ASYMMETRIC BISAMINOQUINOLINES AND BISAMINOQUINOLINES WITH VARIED LINKERS AS AUTOPHAGY INHIBITORS FOR CANCER AND OTHER THERAPY<br/>[FR] BISAMINOQUINOLINES ASYMÉTRIQUES ET BISAMINOQUINOLINES COMPORTANT DIVERSES SÉQUENCES DE LIAISON POUVANT ÊTRE UTILISÉES EN TANT QU'INHIBITEURS DE L'AUTOPHAGIE POUR LE TRAITEMENT DU CANCER ET D'AUTRES MALADIES
申请人：UNIV PENNSYLVANIA
公开号：WO2016022956A1
公开（公告）日：2016-02-11
The invention provides novel asymmetric and symmetric bisaminoquinolmes and related compounds, methods of treatment and syntheses. The novel compounds exhibit effective anticancer activity and are useful in the treatment of a variety of autophagy-related disorders.
INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHEREIN THE PI IS COMPRISED FORM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS
申请人：ADOCIA
公开号：US20190275115A1
公开（公告）日：2019-09-12
In one embodiment, the composition according to the invention is characterized in that the co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical -Hy is chosen among the co-polyamino acids according to formula XXXb hereinafter:
wherein,
D represents, independently, either a group —CH
2
— (aspartic acid) or a group —CH
2
—CH
2
— (glutamic acid),
X represents a cationic entity chosen in the group comprising alkali cations,
R
b
and R
b
′, identical or different, are either a hydrophobic radical -Hy, or a radical chosen in the group consisting of an H, a C2 to C10 linear acyl group, a C3 to C10 branched acyl group, a benzyl, a terminal “amino acid” unit and a pyroglutamate,
at least one of Rb and R′b is a hydrophobic radical -Hy,
Q and Hy are as defined above.
n+m represents the degree of polymerization DP of the co-polyamino acid, namely the mean number of monomeric units per co-polyamino acid chain and 5≤n+m≤250.
在一种实施例中，根据本发明的组合物的特征在于，共聚氨基酸带有羧酸盐基团和至少一种疏水基团-Hy，所述疏水基团-Hy是从下文公式XXXb中的共聚氨基酸中选择的：
其中，
D分别表示一个基团—CH
2
—（天冬氨酸）或一个基团—CH
2
—CH
2
—（谷氨酸），
X表示从包括碱金属阳离子在内的阳离子实体中选择的一个阳离子实体，
R
b
和R
b
′，相同或不同，要么是一个疏水基团-Hy，要么是从包括H、C2到C10线性酰基团、C3到C10支链酰基团、苄基、末端“氨基酸”单元和吡咯谷氨酸在内的基团中选择的一个基团，
Rb和R′b中至少一个是疏水基团-Hy，
Q和Hy如上所定义。
n+m表示共聚氨基酸的聚合度DP，即每个共聚氨基酸链上的单体单位的平均数，且5≤n+m≤250。
[EN] PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN OF WHICH THE PI IS FROM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS AND A LIMITED AMOUNT OF M-CRESOL<br/>[FR] SOLUTION INJECTABLE DE PH 7 COMPRENANT AU MOINS UNE INSULINE BASALE À PI COMPRIS ENTRE 5,8 ET 8,5 ET UN ACIDE CO-POLYAMINO PORTANT DES CHARGES CARBOXYLATE ET DES RADICAUX HYDROPHOBES ET UNE QUANTITÉ LIMITÉE DE M-CRÉSOL
申请人：ADOCIA
公开号：WO2020115333A1
公开（公告）日：2020-06-11
The invention relates to physically stable compositions in the form of an injectable aqueous solution, the pH of which is from 6.0 to 8.0, comprising at least: a) a basal insulin whose isoelectric point (pI) is from 5.8 to 8.5, b) m-cresol in a concentration lower than or equal to 30 mM (0 < [m-cresol] ≤ 30 mM), and c) a co-polyamino acid bearing carboxylate charges and at least one Formula X hydrophobic radical.
POLYMER-CARBOHYDRATE CONJUGATES FOR DRUG DELIVERY TECHNOLOGY
申请人：Wu Nian
公开号：US20150157721A1
公开（公告）日：2015-06-11
The invention comprises compounds, methods of making, and methods of using. The compounds may have a linear or cylic backbone and three or four appended functional groups: one or two lipohilic compounds including sterols or “fat soluble” vitamins, one or two hydrophilic polymer, and one or two carbohydrate. A group of polymer-carbohydrate conjugates having a central backbone and three appended functional groups are disclosed wherein one lipophilic compound is void of both steroid acids. The conjugate may have fatty acids as the primary lipophilic carrier, one hydrophilic polymer, and one carbohydrate. Specific functional groups may be selected for specific applications in formulating pharmaceuticals, cosmetics, nutriceuticals, and the like. Typical coupling reaction of the conjugates may involve one or more or combinations or in series of alkylation including N-alkylation or O-alkylation, etherification, esterification and amidation chemical processes. A variety of linkers between the backbone and functional groups may also be selected to modify the carriers or center backbones for the coupling reactions and optimize performance of the conjugates.
